13F Data
13F filer · CIK 1559565

Sofinnova Management VIII, L.L.C.

Menlo Park, CA · filing since Q4 2016 · last filing Feb 14, 2018
Reported value
$178.4M
$-11.2M vs prior
Positions
9
New / sold out
0 / 1
Added / reduced
0 / 1
Turnover
0.0%
buys $0 · sells $942.5K
Top-10 weight
100.0%

Biggest buys vs Q1 2017

No new or increased positions this quarter.

Biggest sells vs Q1 2017

ChangeSecurityShares changeChange %Est. trade value
Sold outSophiris Bio Inc.-200,000-100.0%$-566.0K
ReducedSpark Therapeutics, Inc.-6,302-0.9%$-376.5K

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2016: $177.7MQ1 2017: $189.6MQ2 2017: $178.4MQ3 2017: $164.0MQ4 2017: $183.2M
Q4 2016Q4 2017

Holdings · Q2 2017

#SecuritySharesValueWeight
1Aclaris Therapeutics, Inc.COMMON STOCK1,539,480$41.8M23.40%
2Spark Therapeutics, Inc.COMMON STOCK693,128$41.4M23.20%
3ObsEva SACOMMON STOCK3,749,623$32.1M17.97%
4Versartis, Inc.COMMON STOCK1,563,260$27.3M15.29%
5Natera, Inc.COMMON STOCK1,550,280$16.8M9.43%
6Auris Medical Holding AGCOMMON SHARES7,818,175$5.6M3.15%
7Mirna Therapeutics, Inc.COMMON STOCK2,974,812$5.0M2.78%
8Innocoll Holdings PLCORDINARY SHARES2,103,173$4.8M2.69%
9Histogenics CorporationCOMMON STOCK2,077,040$3.7M2.08%